1. Academic Validation
  2. Targeting of the FOXM1 Oncoprotein by E3 Ligase-Assisted Degradation

Targeting of the FOXM1 Oncoprotein by E3 Ligase-Assisted Degradation

  • J Med Chem. 2021 Dec 9;64(23):17098-17114. doi: 10.1021/acs.jmedchem.1c01069.
Guoshun Luo 1 Xin Lin 1 Antonio Vega-Medina 2 Maoxu Xiao 1 Guolong Li 1 Hanlin Wei 1 Carlos A Velázquez-Martínez 2 Hua Xiang 1
Affiliations

Affiliations

  • 1 State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, P. R. China.
  • 2 Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6W1W7, Canada.
Abstract

The transcription factor FOXM1 that regulates multiple proliferation-related genes through selective protein-DNA and protein-protein interactions is now considered an attractive oncotarget. There are several small-molecule inhibitors that indirectly suppress the expression of FOXM1 or block its DNA binding domain (FOXM1-DBD). However, insufficient specificity or/and efficacy are two potential drawbacks. Here, we employed in silico modeling of FOXM1-DBD with inhibitors to enable the design of an effective CRBN-recruiting molecule that induced significant FOXM1 protein degradation and exerted promising in vivo antitumor activity against TNBC xenograft models. This study is the first of its kind showcasing the use of an approach described in the literature as protein-targeting chimeras to degrade the elusive FOXM1, providing an alternative strategy to counter the pathological effects resulting from the increased transcriptional activity of FOXM1 observed in Cancer cells.

Figures
Products